MAN2B2

Epididymis-specific alpha-mannosidase · Q9Y2E5 · MAN2B2 on Sugi Atlas →

277 patent compounds predicted against MAN2B2, 230 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Duvoglustat (SCHEMBL2969)	1.00	1/20
Duvoglustat (SCHEMBL142573)	1.00	1/20
Deoxymannojirimycin (SCHEMBL329674)	1.00	1/20
Duvoglustat (SCHEMBL1479364)	1.00	1/20
Duvoglustat (SCHEMBL1527007)	1.00	1/20
Duvoglustat (SCHEMBL1527009)	1.00	1/20
Duvoglustat (SCHEMBL2163281)	1.00	1/20
Duvoglustat (SCHEMBL2434068)	1.00	1/20
Deoxymannojirimycin (SCHEMBL3367857)	1.00	1/20
Deoxymannojirimycin (SCHEMBL4323978)	1.00	1/20
Duvoglustat (SCHEMBL4330678)	1.00	1/20
Duvoglustat (SCHEMBL4619759)	1.00	1/20
Duvoglustat (SCHEMBL8010302)	1.00	1/20
Duvoglustat (SCHEMBL9015606)	1.00	1/20
Duvoglustat (SCHEMBL9290667)	1.00	1/20
Duvoglustat (SCHEMBL9620329)	1.00	1/20
Duvoglustat (SCHEMBL9620331)	1.00	1/20
Duvoglustat (SCHEMBL10028910)	1.00	1/20
Duvoglustat (SCHEMBL12017698)	1.00	1/20
Duvoglustat (SCHEMBL12017699)	1.00	1/20

Clinical trials — most relevant to MAN2B2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)	PHASE4	COMPLETED
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men	PHASE3	ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG	PHASE2	COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis	PHASE2	COMPLETED
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia	PHASE1	WITHDRAWN
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia	PHASE1	WITHDRAWN
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Testicular Proteins for Sperm Retrieval Prediction Protein1, Testis-Expressed Gene 101, and Lectin Galactoside-binding Protein in Predicting Surgical Sperm Retrieval in Men With Non-Obstructive Azoospermia	nan	UNKNOWN
Epididymal U.S Findings in Asthenozoospermic &Correlation With L.Carnitine Level	nan	UNKNOWN
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Seminal Level of Clusterin Before Testicular Sperm Extraction	nan	UNKNOWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Study of Sperm Molecular Factors Implicated in Male Fertility	nan	COMPLETED
Clinical Biomarkers in Alpha-mannosidosis	nan	COMPLETED
Genetic Studies Spermatogenic Failure	nan	COMPLETED
Vitamin D Level vs Semen Parameters	nan	UNKNOWN
Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops	nan	RECRUITING
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3	nan	RECRUITING
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAN2B2 binder may also engage these)

Protein	Name	Similarity
Q5RDJ3	—	1.000	Q5RDJ3 →
O54782	—	1.000	O54782 →
Q28949	—	1.000	Q28949 →
Q9TTK6	—	0.984	Q9TTK6 →
INSRR	Insulin receptor-related protein	0.982	landscape →
GLA	Alpha-galactosidase A	0.981	landscape →
Q6P7A9	—	0.981	Q6P7A9 →
Q5R7A9	—	0.980	Q5R7A9 →
O46432	—	0.979	O46432 →
Q5M936	—	0.978	Q5M936 →
Q24451	—	0.978	Q24451 →
Q2VQV9	—	0.978	Q2VQV9 →
AOC3	Amine oxidase [copper-containing] 3	0.978	landscape →
O94910	—	0.978	O94910 →
GAA	Lysosomal alpha-glucosidase	0.978	landscape →
Q9Z2Y2	—	0.977	Q9Z2Y2 →
P27046	—	0.977	P27046 →
Q9QWR8	—	0.977	Q9QWR8 →
Q9Z2Q3	—	0.977	Q9Z2Q3 →
Q9DBX3	—	0.977	Q9DBX3 →
Q8BYG9	—	0.977	Q8BYG9 →
Q64716	—	0.976	Q64716 →
O73791	—	0.976	O73791 →
Q6ZSI9	—	0.976	Q6ZSI9 →
P48441	—	0.976	P48441 →
O97831	—	0.976	O97831 →
B1AVD1	—	0.976	B1AVD1 →
Q5ZHX9	—	0.976	Q5ZHX9 →
Q9JJ61	—	0.976	Q9JJ61 →
O09159	—	0.976	O09159 →